Skip to main content
Premium Trial:

Request an Annual Quote

Perlegen and GSK Launch Pharmacogenomics Collaboration

NEW YORK, Sept. 18-Perlegen will work with GlaxoSmithKline in a whole genome scanning project to identify drug response markers, the company said today.

 

The collaboration is based upon Perlegen's technique for using high-density microarrays for sequencing, SNP discovery, and haplotype identification. It will "complement" GSK's in-house research, a company representative said in a statement.

 

Using this technique, Perlegen says it can sequence an entire genome in ten days.

 

The companies did not disclose the financial details of this collaboration.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.